Cargando…

A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy

INTRODUCTION: Immune checkpoint inhibitors (ICIs) represent an important advance in the treatment of melanoma. ICIs may induce autoimmune phenomena caused by concurrent activation of the immune system against normal cells. During the last years, cases of musculoskeletal side effects, especially immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papaxoinis, George, Anastasopoulou, Amalia, Laskari, Katerina, Diamantopoulos, Panagiotis, Benopoulou, Olga, Gogas, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7478575/ https://www.ncbi.nlm.nih.gov/pubmed/32150095 http://dx.doi.org/10.1097/MD.0000000000019439

Ejemplares similares

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Challenges in the treatment of melanoma with BRAF and MEK inhibitors in patients with sickle cell disease: case report and review of the literature
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature
por: Anastasopoulou, Amalia, et al.
Publicado: (2021)

Clinical course of COVID-19 infection in a melanoma patient treated with nivolumab and bempegaldesleukin: a case report
por: Anastasopoulou, Amalia, et al.
Publicado: (2022)

Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2020)

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
por: Petrelli, Fausto, et al.
Publicado: (2016)

Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report
por: Liu, Shiwei, et al.
Publicado: (2022)

When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
por: Anastasopoulou, Amalia, et al.
Publicado: (2019)

Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Melanoma Treated with Immunotherapy
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Identification of hub gene and lncRNA signature related to entotic cell death in cutaneous melanoma for prognostic and immune prediction
por: Zhang, Chen, et al.
Publicado: (2023)

Factors associated with immune checkpoint inhibitor use among older adults with late-stage melanoma: A population-based study
por: Rai, Pragya, et al.
Publicado: (2021)

Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
por: Ziogas, Dimitrios C, et al.
Publicado: (2020)

GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report
por: Patel, Sapna P., et al.
Publicado: (2016)

Construction of autophagy prognostic signature and analysis of prospective molecular mechanisms in skin cutaneous melanoma patients
por: Liao, Shian, et al.
Publicado: (2021)

Using temporal heatmaps to identify worthwhile articles on immune checkpoint blockade for melanoma (ICBM) in Mainland China, Hong Kong, and Taiwan since 2000: A bibliometric analysis
por: Juang, Shiow-Jen, et al.
Publicado: (2023)

Immune-related adverse events with immune checkpoint inhibitors: Special reference to the effects on the lungs
por: Hirata, Aya, et al.
Publicado: (2021)

Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma
por: Oba, Junna, et al.
Publicado: (2016)

Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma
por: Xin, Yong, et al.
Publicado: (2016)

Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2
por: Ding, Zhenhua, et al.
Publicado: (2015)

Endobronchial melanoma metastasis 40 years after the excision of the primary cutaneous tumor: A case report
por: Karpathiou, Georgia, et al.
Publicado: (2017)

Identification of lactylation gene CALML5 and its correlated lncRNAs in cutaneous melanoma by machine learning
por: Feng, Hailiang, et al.
Publicado: (2023)

Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature
por: Song, Jin-cheng, et al.
Publicado: (2017)

Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade
por: Shen, Yanyun, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

A new immune checkpoint-associated nine-gene signature for prognostic prediction of glioblastoma
por: Jin, Xiao, et al.
Publicado: (2023)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy
por: Hannan, Enda J., et al.
Publicado: (2017)

Immune-related lncRNA pairs as novel signature to predict prognosis and immune landscape in melanoma patients
por: Li, Zhehong, et al.
Publicado: (2022)

Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy
por: Gouveris, Panagiotis, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
por: Gao, Loulu, et al.
Publicado: (2022)

Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report
por: An, Gaili, et al.
Publicado: (2023)

Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review
por: Pu, Dan, et al.
Publicado: (2020)

Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report
por: Wang, Chen, et al.
Publicado: (2023)

Multichamber Involvement of Metastatic Cardiac Melanoma
por: Bonou, Maria S., et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Changes of IL-6 And IFN-γ before and after the adverse events related to immune checkpoint inhibitors: A retrospective study
por: Zhang, Xu, et al.
Publicado: (2022)

The effect of pretreatment BMI on the prognosis and serum immune cells in advanced LSCC patients who received ICI therapy
por: Wang, Fei, et al.
Publicado: (2021)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6qpb5b7lhri7uavvaig75779qk